Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness and Safety of NBI-1065845 for Adults with Major Depressive Disorder

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest in daily activities. The treatment being tested is a medication called NBI-1065845, which is taken in tablet form. The study will compare the effects of this medication to a placebo to determine its effectiveness and safety when used alongside existing antidepressant treatments.

The purpose of the study is to evaluate how well NBI-1065845 can improve symptoms of depression in individuals with MDD. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for a total of 56 days, during which participants will continue their current antidepressant medications while taking the study medication or placebo.

Throughout the study, participants will be monitored to assess changes in their depression symptoms using a tool called the Montgomery-Asberg Depression Rating Scale (MADRS). The study aims to see if there is a significant improvement in depression symptoms by the end of the 56-day period. Additionally, other measures of daily functioning and overall severity of depression will be evaluated to provide a comprehensive understanding of the treatment's impact.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Beginning of the trial

    Upon joining the study, you will be asked to confirm your understanding and agreement to participate by completing an informed consent form. This ensures that you are aware of the study's purpose and procedures.

  2. Step 2

    Initial assessment

    You will undergo an initial assessment to confirm your eligibility. This includes a face-to-face evaluation using the Mini-International Neuropsychiatric Interview to confirm a diagnosis of major depressive disorder or persistent depressive disorder.

    Your current treatment with oral antidepressants will be reviewed to ensure it meets the study's criteria. An assessment of your response to these treatments will be conducted using the Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire.

  3. Step 3

    Baseline measurements

    Baseline measurements will be taken, including your score on the Hamilton Depression Rating Scale-17 Item, which must be 22 or higher. This will help establish a starting point for evaluating changes during the study.

  4. Step 4

    Randomization and treatment

    You will be randomly assigned to receive either the study medication, NBI-1065845, or a placebo. The medication is in tablet form and is taken orally.

    The study medication or placebo will be administered over a period of 56 days. The specific dosage and frequency will be provided by the study team.

  5. Step 5

    Ongoing assessments

    Throughout the study, regular assessments will be conducted to monitor your progress. These include evaluations of your symptoms using the Montgomery-Asberg Depression Rating Scale and other relevant scales.

    Your safety and any side effects will be closely monitored by the study team.

  6. Step 6

    End of treatment evaluation

    At the end of the 56-day treatment period, a final evaluation will be conducted to assess changes in your symptoms and overall condition.

    The primary focus will be on the change in your Montgomery-Asberg Depression Rating Scale score from the beginning to the end of the study.

Who can join the trial?

7 criteria

  • Completed informed consent, which means you understand the study and agree to participate.
  • Must be at least 18 years old at the time of agreeing to participate.
  • Have a primary diagnosis of recurrent Major Depressive Disorder (MDD) or persistent depressive disorder. This diagnosis must be confirmed through a face-to-face interview using a specific questionnaire.
  • Currently receiving oral antidepressant treatment(s) as specified in the study guidelines.
  • Have had an Inadequate Response (IR) to oral antidepressant treatments during the current episode of depression. This means the treatments did not work well enough, as assessed by a specific questionnaire.
  • Have a Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score of 22 or higher at the start of the study. This is a questionnaire used to measure the severity of depression.
  • Willing and able to follow all study procedures and restrictions, according to the study doctor's opinion.

Who cannot join the trial?

10 criteria

  • Patients who do not have a diagnosis of Major Depressive Disorder cannot participate.
  • Patients who are not within the specified age range cannot participate.
  • Patients who are not willing to comply with the study requirements cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with certain medical conditions that might interfere with the study cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients who have a history of substance abuse or dependency cannot participate.
  • Patients who have a history of severe allergic reactions cannot participate.
  • Patients who have a history of certain psychiatric disorders cannot participate.
  • Patients who have a history of non-compliance with medical treatments cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NBI-1065845 is a medication being tested to see if it can help people with Major Depressive Disorder (MDD) feel better when used alongside their regular treatment. This study is looking at how well this medication works to improve symptoms of depression. The goal is to see if people taking this medication feel less depressed compared to those who do not take it. The study measures changes in depression symptoms using a specific scale called the Montgomery-Asberg Depression Rating Scale (MADRS). This medication is being tested to see if it can be a helpful addition to the usual treatments for depression.

What is already known about the treatment

NBI-1065845 – NBI-1065845 is administered orally and is currently being studied as an additional treatment for individuals with Major Depressive Disorder (MDD). In medical research, it is being evaluated for its effectiveness in reducing symptoms of depression when used alongside other treatments. The main therapeutic indication for NBI-1065845 is to help improve mood and alleviate depressive symptoms in people with MDD. At the molecular level, it works by influencing certain chemicals in the brain that are linked to mood regulation. It is classified pharmacologically as an adjunctive treatment for depression.

Investigated diseases

Major Depressive Disorder – Major Depressive Disorder is a mental health condition characterized by persistent feelings of sadness and a lack of interest in activities once enjoyed. It affects how a person feels, thinks, and handles daily activities, such as sleeping, eating, or working. The disorder often involves a range of emotional and physical problems, leading to a decrease in a person’s ability to function at work and home. Symptoms may include changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and recurrent thoughts of death. The progression of the disorder can vary, with some individuals experiencing episodes that last for weeks or months, while others may have symptoms that persist for years. The severity and impact of the disorder can fluctuate over time, with periods of remission and recurrence.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-519418-29-00Protocol codeNBI-1065845-MDD3024Estimated enrolment200 patientsSponsorNeurocrine Biosciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).